ICICI Direct has given buy rating to the stock of Granules India Ltd for a strong gain of 23% with a target price of Rs 375 apiece. The market capitalization is Rs 7708 crore.
ICICI Direct has given buy rating to the stock of Granules India Ltd for a strong gain of 23% with a target price of Rs 375 apiece. The market capitalization is Rs 7708 crore. Granules' share price has grown by approximately 2.8x over the past five years (from approximately Rs 109 in August 2017 to approximately Rs 304 levels in August 2022).
1. Granules India Ltd Stock Outlook
The current market price of the stock is Rs 310 apiece with a 52-week high of Rs 377 apiece and 52-week low at Rs 227 apiece. The stock gained 1.35% in trading yesterday (August 12, 2022).
Multibagger returns: It has given multibagger returns over the years. In last 5 years, the stock has given a return of 184% and in last 3 years the stock has given a return of 222%. The stock has fallen 17% in last 1 year.
According to ICICI Direct, if you buy the stock now at its current market price, it has the potential to reach its target price of Rs 375 apiece in a period of 12 months.
2. Granules India Ltd Q1FY23 Results
Granules' revenue growth in this quarter was mainly driven by volume growth in most markets and also on account of new launches in the US. Sales were up 20% YoY to Rs 1019.6 crore. EBITDA was at Rs 211.5 crore, up 5% YoY with margins at 20.7%. Adjusted PAT was at Rs 127.6 crore (up 6.1% YoY).
3. Granules India Ltd Valuation
According to ICICI Direct, "We maintain BUY rating as Granules 1) focus on backward integration, 2) initiatives like passing on price hike to customers, 3) compelling risk-reward matrix based on FY24E earnings."
4. About Granules India Ltd
Granules is a large-scale vertically integrated company that manufactures API or active pharmaceutical ingredients, intermediates and finished dosages and has seven manufacturing facilities along with B2B & B2C marketing & distribution. Top five products (Paracetamol, Ibuprofen, Metformin, Methocarbamol, Guaifenesin) contributed 81% to FY22 revenues.
Disclaimer
The stock has been picked from the brokerage report of ICICI Direct. Greynium Information Technologies, the Author, and the respective Brokerage House are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.
More From GoodReturns

ATM Rules Changing From April 1, 2026: HDFC Bank, PNB, Bandhan Bank & Others Revise Cash Withdrawal Rules

Indane, HP & Bharat Gas Cylinder Booking Rules: OTP Mandatory After LPG Refilling Gap Increased to 25-45 Days

Crash in Gold Rate in India by Rs 71,400 in Single Day; Will Gold Price Today Fall Below Rs 1.50 Lakh? Outlook

Gold & Silver Rates Today Live: MCX Gold Crashes By Rs 5,645, Silver Falls By Rs 16,540; 24K, 22K, 18K Gold

1:5 Split Soon? Vedanta Ltd To Consider 3rd Interim Dividend On March 23, Share Jumps; Record Date & Buy Call

Sleeper Vande Bharat Express New Routes Identified for Long Distance Travel

Gold & Silver Rates Today Live Updates: Will 24 Carat, 22 Carat, 18 Carat See Bullish Week Ahead?

Mega Gold Price Crash Alert! 24K Sinks Rs 1.36 Lakh/100 Gm In Week; Silver Sees Losses | March 23-27 Outlook

Gold & Silver Rates Today Live: MCX Gold Ends Above Rs 1.40 Lakh, Silver Up 1%; 24K, 22K, 18K Gold On March 24

Gold Rate Crashes Over Rs 1 Lakh in Single Day, Slips to Lowest Since January; Will Gold Price Today Decline?

Gold Price Crash May Fuel Jewellery Demand: Why Kalyan Jewellers Share Price Could Shine Despite 5% Dip



Click it and Unblock the Notifications